{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T04:18:19Z","timestamp":1744863499749,"version":"3.40.4"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Introduction To analyze our outcome for patients with neovascular age-related macular degeneration (nAMD) treated with aflibercept in a treat-and-extend regimen pursuing an exit strategy (with best possible adherence to the \u201cBern\u201d exit criteria) over 6 years in a real-world setting. The primary objective of the study was to investigate the proportion of patients who were able to achieve and maintain treatment exit.<\/jats:p><jats:p>\n          Methods This is a retrospective chart review study of treatment-na\u00efve patients diagnosed with nAMD receiving intravitreal aflibercept injections performed at our department with at least 2 years of follow-up visits. The primary outcome was the percentage of patients able to achieve and maintain the treatment exit regarding intravitreal anti-VEGF injections. Further outcome measures were best-corrected visual acuity (BCVA), incidence of recurrence after treatment cessation, duration of therapy, and number and intervals of injections.<\/jats:p><jats:p>\n          Results There were 31 eyes of 25 patients included in this retrospective study. The observation period was from September 1, 2017 to August 31, 2023. Of all included patient eyes, 22.6% (n\u2009=\u20097) reached exit criteria. Of all the \u201cexit\u201d patients, 28.6% (n\u2009=\u20092) suffered from disease relapse and therapy was restarted at a mean (\u00b1\u2009SD) of 41.5\u2009\u00b1\u200912.5 weeks (range: 29 to 54 weeks). Regarding the eyes that met treatment exit, 5 of 31 (16.1%) had no disease recurrence in the observed study period. The median BCVA (Snellen decimal; \u00b1 interquartile range: IQR) changed from 0.63 (0.27) at baseline to 0.63 (0.4) in the first year, 0.63 (0.3) in the second year, 0.63 (0.46) in the third year, 0.63 (0.3) in the fourth year, 0.63 (0.4) in the fifth year, and 0.4 (0.04) in the sixth year. The median number of injections (\u00b1 IQR) per eye in the first year of treatment was 8 (2), in the second year 5 (2), in the third year 5 (2.5), in the fourth year 5 (1), in the fifth year 3 (0.8), and\n          in the sixth year 3 (0). Extension of the treatment interval after the loading phase in weeks was achieved up to a median (\u00b1\u2009IQR) of 5.8 (4) in the first year, 8.4 (6) in the second year, 8 (5.7) in the third year, 9.4 (5.6) in the fourth year, 7 (6.9) in the fifth year, and 8.4 (3.1) in the sixth year of observation.<\/jats:p><jats:p>\n          Discussion Our study indicates a lower rate of patients reaching exit criteria with a treat-and-extend regimen compared to clinical study settings, and a similar recurrence rate of nAMD after treatment cessation. Nonadherence to a strict treat-and-extend protocol might influence the result.<\/jats:p>","DOI":"10.1055\/a-2511-5899","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:16:46Z","timestamp":1738801006000},"page":"398-404","source":"Crossref","is-referenced-by-count":0,"title":["Exit Strategy for Treatment of Neovascular Age-Related Macular Degeneration in a Real-World Setting: Wishful Thinking?"],"prefix":"10.1055","volume":"242","author":[{"given":"Michael","family":"Eastline","sequence":"additional","affiliation":[{"name":"Eye Clinic Wettingen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadiq","family":"Said","sequence":"additional","affiliation":[{"name":"Eye Clinic Wettingen, Switzerland"},{"name":"Department of Ophthalmology, University Hospital Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina Monika","family":"Bosch","sequence":"additional","affiliation":[{"name":"Eye Clinic Wettingen, Switzerland"},{"name":"Department of Ophthalmology, University Hospital Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Knecht-Bosch","sequence":"additional","affiliation":[{"name":"Eye Clinic Wettingen, Switzerland"},{"name":"Department of Ophthalmology, University Hospital Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"W L Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e29583","DOI":"10.7759\/cureus.29583","article-title":"Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment","volume":"14","author":"H Vyawahare","year":"2022","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3390\/ijms22031170","article-title":"Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy","volume":"22","author":"A Pugazhendhi","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"03","key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub4","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"S D Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"P J Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research Group","year":"2011","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"J S Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/IAE.0000000000000717","article-title":"Societal Costs Associated with Neovascular Age-Related Macular Degeneration in the United States","volume":"36","author":"M M Brown","year":"2016","journal-title":"Retina"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0974-9233.173133","article-title":"Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials","volume":"23","author":"A Agarwal","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/APO.0000000000000445","article-title":"Treat-and-Extend Regimens for the Management of Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy: Consensus and Recommendations From the Asia-Pacific Vitreo-retina Society","volume":"10","author":"V Chaikitmongkol","year":"2021","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"05","key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012208.pub2","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","author":"E Li","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of Real-World Outcomes of Intravitreal Ranibizumab for the Treatment of Neovascular Age-Related Macular Degeneration","volume":"36","author":"L N Kim","year":"2016","journal-title":"Retina"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1159\/000452929","article-title":"Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration","volume":"236","author":"H Giannakaki-Zimmermann","year":"2016","journal-title":"Ophthalmologica"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00417-019-04404-0","article-title":"Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study","volume":"257","author":"M Augsburger","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/bjophthalmol-2020-316514","article-title":"Aflibercept for age-related macular degeneration: 4-year outcomes of a \u2018treat-and-extend\u2019 regimen with exit-strategy","volume":"106","author":"D Jaggi","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","article-title":"Exit Strategy in a Treat-and-Extend Regimen for Exudative Age-Related Macular Degeneration","volume":"39","author":"P Arendt","year":"2019","journal-title":"Retina"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1136\/bjophthalmol-2013-304775","article-title":"Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen","volume":"98","author":"M N Menke","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group","volume":"127","author":"R F Spaide","year":"2020","journal-title":"Ophthalmology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR: A Randomized Controlled Trial","volume":"37","author":"M Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12886-018-1005-x","article-title":"Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia","volume":"18","author":"P Jaki Mekjavi\u0107","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40123-020-00300-7","article-title":"Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study","volume":"9","author":"J Ruys","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.oret.2017.01.004","article-title":"Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: VIEW 1 Extension Study","volume":"1","author":"P K Kaiser","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e000109","DOI":"10.1136\/bmjophth-2017-000109","article-title":"Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study","volume":"4","author":"M Weber","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","article-title":"Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a \u201cTreat-and-Extend\u201d Regimen","volume":"3","author":"P G Traine","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ophtha.2007.05.028","article-title":"Comparison of visual acuity in macular degeneration patients measured with snellen and early treatment diabetic retinopathy study charts","volume":"115","author":"I A Falkenstein","year":"2008","journal-title":"Ophthalmology"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2511-5899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T22:41:07Z","timestamp":1744843267000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2511-5899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":25,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2511-5899","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"type":"print","value":"0023-2165"},{"type":"electronic","value":"1439-3999"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}